Company Valuation: ZyVersa Therapeutics, Inc.

Data adjusted to current consolidation scope
Fiscal Period: December 2022 2023 2024 2025
Market Cap 1 14.26 4.719 2.659 1.082
Change - -66.9% -43.66% -59.32%
Enterprise Value (EV) 1 8.465 1.59 1.128 0.9798
Change - -81.22% -29.07% -13.12%
P/E -2.6x -0.01x -0.12x -0.03x
PBR 0.15x 0.33x 0.31x -0.09x
PEG -0x -0x 0x 0x
Capitalization / Revenue - - - -
EV / Revenue - - - -
EV / EBITDA -0.73x -0.11x -0.12x -0.14x
EV / EBIT -0.72x -0.11x -0.12x -0.14x
EV / FCF - - - -
FCF Yield - - - -
Dividend per Share 2 - - - -
Rate of return - - - -
EPS 2 -211.2 -1,090 -8.48 -4.184
Distribution rate - - - -
Net sales - - - -
EBITDA 1 -11.67 -14.41 -9.13 -6.838
EBIT 1 -11.68 -14.42 -9.137 -6.845
Net income 1 -14.12 -98.3 -9.413 -24.95
Net Debt 1 -5.793 -3.129 -1.531 -0.1018
Reference price 2 549.5005 9.0000 1.0600 0.1336
Nbr of stocks (in thousands) 25.9 524 2,508 8,096
Announcement Date 3/31/23 3/25/24 3/27/25 3/31/26
1USD in Million2USD
Estimates

P/E (Y) EV / Sales (Y) EV / EBITDA (Y) Dividend Yield (Y) Capi.($)
- - - - 818K
21.25x6.51x14.24x1.5% 56.54B
31.6x7.8x24.02x0.05% 53.6B
-17.91x4.18x-7.32x-.--% 22.91B
-38.06x12.21x-36.05x-.--% 21.37B
25.45x4.98x13.18x-.--% 20.27B
24.28x4.73x15.36x-.--% 17.56B
-737.38x35.03x-3943.97x-.--% 14.75B
40.7x16.37x42.16x0.09% 13.53B
16.73x4.82x11.24x-.--% 13.33B
Average -70.37x 10.74x -429.68x 0.18% 23.39B
Weighted average by Cap. -32.01x 9.11x -238.39x 0.38%

Y-o-Y evolution of P/E

Historical PBR trend

Evolution Enterprise Value / Sales

Change in Enterprise Value/EBITDA

  1. Stock Market
  2. Stocks
  3. ZVSA Stock
  4. Valuation ZyVersa Therapeutics, Inc.